Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05607719 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Inhaled Corticosteroids (ICS) on Pulmonary Endothelial Function in COPD

StatusCompleted
PhasePhase 2
Started2023-04-11
View on ClinicalTrials.gov ↗

Amendment history

2026-09-02
Study Status, Study Design v11
Trial completed
Final enrollment: 25 participants (planned 30)
Enrollment targetestimated 30→confirmed 25
2026-06-17
Study Status v10
Primary completion pushed: 2026-06-30 → 2026-07-31
Completion pushed: 2026-06-30 → 2026-07-31
2026-04-20
Study Status, Contacts/Locations v9
Trial status changed: Recruiting → Active, Not Recruiting
Primary completion moved earlier: 2026-12-31 → 2026-06-30
Completion moved earlier: 2026-12-31 → 2026-06-30
Study sitesdetails revised at 1 of 1 site
2026-01-08
Study Status v8
Primary completion date2025-12-31→2026-12-31
Completion date2026-03-30→2026-12-31
2025-01-17
Study Status v7
Primary completion date2025-01-31→2025-12-31
Completion date2025-04-30→2026-03-30
Show 6 earlier versions
2024-11-21
Study Status v6
Re-verified, no change to tracked fields
2023-12-14
Study Status v5
Primary completion date2024-01→2025-01-31
Completion date2024-01→2025-04-30
2023-04-12
Study Status v4
Start dateestimated 2023-05→confirmed 2023-04-11
2023-02-14
Study Identification, Study Status v3
Primary completion date2024-01-10→2024-01
Completion date2024-01-10→2024-01
Start date2023-02-25→2023-05
2023-01-23
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Start date2023-01-10→2023-02-25
Study sitesdetails revised at 1 of 1 site
2022-12-15
Study Status v1
Re-verified, no change to tracked fields
2022-11-02
Original filing
University of Miami
241 trials monitored
See 29 trials at risk
COPD
1,057 trials monitored
See 28 trials at risk
The study objective is to determine whether an ICS added for 4 weeks to a baseline treatment with a Long-Acting Beta-adrenergic Agonist (LABA) and Long-Acting Muscarinic Antagonist (LAMA) combination improves pulmonary vascular endothelial function as assessed by the vasodilator response to inhaled albuterol (endothelium-dependent vasodilation) in stable COPD patients treated with a LABA/LAMA without an ICS for at least one month.
Trial Details
NCT Number NCT05607719
Lead Sponsor University of Miami
Collaborators: AstraZeneca
Conditions Chronic Obstructive Pulmonary Disease
Enrollment 25 participants
Start Date 2023-04-11
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-09-08